Research listings · Peptides
ACE-031 research listings: prices and suppliers
Research materials and consumer products belong to different categories. A listing, laboratory report, or research-use label does not establish suitability for personal use.
We have no commercial relationship with suppliers on this page. Offers are sorted by price per mg; commission never changes the order.
Prices observed weekly · How we check prices →
ACE-031 listings
No single-substance listings are tracked for ACE-031 yet.
Research context
From our own records, with the date each was last checked.
- FDA approval
- No approved drug product with this ingredient listed in Drugs@FDA (data updated 2026-11-02)Checked
- 503A / 503B compounding
- Not in any 503A category on FDA's 2026-05-14 listChecked
- Advisory committee (PCAC)
- No PCAC meeting on ACE-031 found on FDA's 2022 to 2027 PCAC meeting pages (checked 2026-11-03)Checked
- Rulemaking / enforcement
- No FDA document found in the Federal Register (search on 2026-11-03); the only matches are FTC notices on the horseracing anti-doping ruleChecked
- WADA
- S4.3 Agents preventing activin receptor IIB activation · Prohibited at all times — in and out of competition (2026 list; unchanged in the 2027 list, in force from Jan 1, 2027)Checked
- Identity
- MW about 77.5 kDa (calculated) · CAS 1169766-01-1Sequence Homodimer; each 343-residue chain is a human activin receptor IIB extracellular-domain fragment, a Gly-Gly-Gly linker and a human IgG1 Fc fragmentSource record Checked
Identity noteA large protein, not a short peptide. A listing's name alone does not show that a vial contains this fusion protein.
How we check prices · Offers are matched to our catalogue by an editor before they appear; a listing is not an endorsement.